Risk Factors of Salvage Procedure for Refractory Morcellation During Holmium Laser Enucleation of the Prostate.
Holmium-YAG Lasers
Morcellation
Prostatectomy
Transurethral resection of prostate
Journal
International neurourology journal
ISSN: 2093-4777
Titre abrégé: Int Neurourol J
Pays: Korea (South)
ID NLM: 101534513
Informations de publication
Date de publication:
Sep 2023
Sep 2023
Historique:
received:
11
04
2023
accepted:
22
06
2023
medline:
6
10
2023
pubmed:
6
10
2023
entrez:
6
10
2023
Statut:
ppublish
Résumé
We aimed to identify the risk factors for salvage procedure (SP) required for refractory adenomatous tissue resistant to morcellation during holmium laser enucleation of the prostate (HoLEP). Patients who underwent HoLEP between January 2010 and April 2020 at Seoul National University Hospital were analyzed. SPs were defined as cases of conversion to resection of the prostatic tissue using an electrosurgical loop after morcellation or secondary morcellation a few days after surgery or conversion to open cystotomy. Among a total of 2,427 patients, 260 were identified as having SP (SP group) (transurethral resection-nodule [n = 250, 96.1%], secondary morcellation a few days after surgery [n = 9, 3.5%], and conversion to open cystotomy [n = 1, 0.4%]). Patients in the SP group were older and had higher 5-α reductase inhibitors use, higher prostate-specific antigen, larger total prostate volume, and larger transition zone volume (TZV) than those in the non-SP group. In the multivariable logistic regression analysis, only age and TZV were associated with SP. Compared to 40s and 50s, the odds ratios (ORs) were 3.84 in 60s (95% confidence interval [CI] 1.37-10.78, P = 0.011), 4.53 in 70s (95% CI, 1.62-12.62, P = 0.004), and 6.59 in 80s or older (95% CI, 2.23-19.46, P = 0.001). The ORs of the SP were analyzed per TZV quartile. Compared to TZV ≤ 20.3 mL, the OR was 3.75 in 32.0 mL < TZV ≤ 50.4 mL (95% CI, 2.00-7.04, P < 0.001) and 8.25 in 50.4 mL < TZV (95% CI, 4.06-16.77, P < 0.001). The risk of refractory morcellation increased in patients aged > 60 years or those with TZV > 32 mL. In order to more efficiently remove these resistant adenomas, it is necessary to develop more efficient morcellators in the future.
Identifiants
pubmed: 37798887
pii: inj.2346076.038
doi: 10.5213/inj.2346076.038
pmc: PMC10556432
doi:
Types de publication
Journal Article
Langues
eng
Pagination
200-206Subventions
Organisme : Ministry of Science and ICT
Organisme : Information Technology Research Center
Organisme : Institute for Information and Communications Technology Planning and Evaluation
ID : IITP-2021-2018-0-01833
Références
Prostate. 2001 Jan 1;46(1):45-51
pubmed: 11170131
Urology. 2001 Dec;58(6 Suppl 1):17-24; discussion 24
pubmed: 11750244
J Urol. 2011 Nov;186(5):1972-6
pubmed: 21944127
Korean J Urol. 2015 Mar;56(3):218-26
pubmed: 25763126
Int Neurourol J. 2015 Jun;19(2):90-8
pubmed: 26126438
Br J Urol. 1998 Dec;82 Suppl 1:26-33
pubmed: 9883259
J Endourol. 2012 Jun;26(6):697-700
pubmed: 22141409
J Urol. 2001 Mar;165(3):1019-26
pubmed: 11176533
J Urol. 1999 Apr;161(4):1174-9
pubmed: 10081864
Urology. 1996 Jan;47(1):48-51
pubmed: 8560662
Eur Urol. 1998;33(1):69-72
pubmed: 9471043
Eur Urol. 2008 Mar;53(3):599-604
pubmed: 17997021
Korean J Urol. 2013 Sep;54(9):570-9
pubmed: 24044089
Prostate. 2015 Feb 15;75(3):233-41
pubmed: 25327615
Eur Urol. 2008 Jan;53(1):160-6
pubmed: 17869409
Investig Clin Urol. 2019 Sep;60(5):333-342
pubmed: 31501795
J Endourol. 1998 Oct;12(5):457-9
pubmed: 9847070
Urology. 1999 Mar;53(3):581-9
pubmed: 10096388
BJU Int. 2002 Dec;90(9):863-9
pubmed: 12460346
J Urol. 1984 Sep;132(3):474-9
pubmed: 6206240
J Urol. 2016 Feb;195(2):413-7
pubmed: 26307163